• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道菌群与胆汁酸相互作用影响糖尿病肾病的进展。

Intestinal flora and bile acid interactions impact the progression of diabetic kidney disease.

机构信息

Department of Nephrology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

出版信息

Front Endocrinol (Lausanne). 2024 Sep 20;15:1441415. doi: 10.3389/fendo.2024.1441415. eCollection 2024.

DOI:10.3389/fendo.2024.1441415
PMID:39371929
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11449830/
Abstract

In recent years, with the rapid development of omics technologies, researchers have shown that interactions between the intestinal flora and bile acids are closely related to the progression of diabetic kidney disease (DKD). By regulating bile acid metabolism and receptor expression, the intestinal flora affects host metabolism, impacts the immune system, and exacerbates kidney injury in DKD patients. To explore interactions among the gut flora, bile acids and DKD, as well as the related mechanisms, in depth, in this paper, we review the existing literature on correlations among the gut flora, bile acids and DKD. This review also summarizes the efficacy of bile acids and their receptors as well as traditional Chinese medicines in the treatment of DKD and highlights the unique advantages of bile acid receptors in DKD treatment. This paper is expected to reveal a new and important potential strategy for the clinical treatment of DKD.

摘要

近年来,随着组学技术的快速发展,研究人员表明肠道菌群与胆汁酸之间的相互作用与糖尿病肾病(DKD)的进展密切相关。肠道菌群通过调节胆汁酸代谢和受体表达,影响宿主代谢,作用于免疫系统,从而加重 DKD 患者的肾脏损伤。为深入探讨肠道菌群、胆汁酸与 DKD 之间的相互作用及其相关机制,本文就肠道菌群、胆汁酸与 DKD 之间相关性的相关文献进行综述,总结胆汁酸及其受体在 DKD 治疗中的作用,并重点阐述胆汁酸受体在 DKD 治疗中的独特优势。本文旨在为 DKD 的临床治疗提供新的潜在策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605a/11449830/2d57c1d49ff1/fendo-15-1441415-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605a/11449830/76bb045c2438/fendo-15-1441415-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605a/11449830/050da7646eab/fendo-15-1441415-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605a/11449830/2d57c1d49ff1/fendo-15-1441415-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605a/11449830/76bb045c2438/fendo-15-1441415-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605a/11449830/050da7646eab/fendo-15-1441415-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605a/11449830/2d57c1d49ff1/fendo-15-1441415-g003.jpg

相似文献

1
Intestinal flora and bile acid interactions impact the progression of diabetic kidney disease.肠道菌群与胆汁酸相互作用影响糖尿病肾病的进展。
Front Endocrinol (Lausanne). 2024 Sep 20;15:1441415. doi: 10.3389/fendo.2024.1441415. eCollection 2024.
2
Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease.低胆汁酸作为 2 型糖尿病伴活检证实的糖尿病肾病患者肾脏结局的独立危险因素。
Front Endocrinol (Lausanne). 2022 Oct 7;13:1026995. doi: 10.3389/fendo.2022.1026995. eCollection 2022.
3
The renal apical sodium-dependent bile acid transporter expression rescue attenuates renal damage in diabetic nephropathy via farnesoid X receptor activation.顶端钠依赖性胆汁酸转运蛋白表达的恢复通过法尼醇 X 受体的激活减轻糖尿病肾病的肾脏损伤。
Nephrology (Carlton). 2024 Oct;29(10):627-635. doi: 10.1111/nep.14338. Epub 2024 Jun 26.
4
Metabolomic profiling reveals the step-wise alteration of bile acid metabolism in patients with diabetic kidney disease.代谢组学分析揭示了糖尿病肾病患者胆汁酸代谢的逐步改变。
Nutr Diabetes. 2024 Oct 9;14(1):85. doi: 10.1038/s41387-024-00315-0.
5
Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice.达格列净通过抑制钠-葡萄糖共转运蛋白 2(SGLT2)改善糖尿病肾病(DKD),这与在 db/db 小鼠中对肠道微生物群的影响增加有关。
Front Endocrinol (Lausanne). 2023 Jan 26;14:1026040. doi: 10.3389/fendo.2023.1026040. eCollection 2023.
6
Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective.糖尿病和非糖尿病肾病患者的肠道微生物多样性:现状与未来展望。
Life Sci. 2023 Mar 1;316:121414. doi: 10.1016/j.lfs.2023.121414. Epub 2023 Jan 20.
7
Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.中医通过靶向肠道微生物群改善糖尿病肾病。
Pharm Biol. 2024 Dec;62(1):423-435. doi: 10.1080/13880209.2024.2351946. Epub 2024 May 17.
8
Effect of gut flora mediated-bile acid metabolism on intestinal immune microenvironment.肠道菌群介导的胆汁酸代谢对肠道免疫微环境的影响。
Immunology. 2023 Nov;170(3):301-318. doi: 10.1111/imm.13672. Epub 2023 Jun 15.
9
Lipid metabolism disorder in diabetic kidney disease.糖尿病肾病中的脂代谢紊乱。
Front Endocrinol (Lausanne). 2024 Apr 29;15:1336402. doi: 10.3389/fendo.2024.1336402. eCollection 2024.
10
The gut microbiome in differential diagnosis of diabetic kidney disease and membranous nephropathy.肠道微生物群在糖尿病肾病与膜性肾病鉴别诊断中的作用
Ren Fail. 2020 Nov;42(1):1100-1110. doi: 10.1080/0886022X.2020.1837869.

引用本文的文献

1
Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions.糖尿病肾病:从发病机制到多模式治疗——当前证据与未来方向
Front Med (Lausanne). 2025 Aug 8;12:1631053. doi: 10.3389/fmed.2025.1631053. eCollection 2025.
2
Metformin Beyond Diabetes: A Precision Gerotherapeutic and Immunometabolic Adjuvant for Aging and Cancer.二甲双胍超越糖尿病:一种针对衰老和癌症的精准老年治疗与免疫代谢辅助药物。
Cancers (Basel). 2025 Jul 25;17(15):2466. doi: 10.3390/cancers17152466.
3
The alternations of gut microbiota in diabetic kidney disease: insights from a triple comparative cohort.

本文引用的文献

1
Modulation of the Serum Metabolome by the Short-Chain Fatty Acid Propionate: Potential Implications for Its Cholesterol-Lowering Effect.短链脂肪酸丙酸盐对血清代谢组的调节:对其降胆固醇作用的潜在影响。
Nutrients. 2024 Jul 22;16(14):2368. doi: 10.3390/nu16142368.
2
alleviates necrotizing enterocolitis through restoring bile acid metabolism balance using bile salt hydrolase and inhibiting FXR-NLRP3 signaling pathway.通过胆汁盐水解酶恢复胆汁酸代谢平衡并抑制 FXR-NLRP3 信号通路来缓解坏死性小肠结肠炎。
Gut Microbes. 2024 Jan-Dec;16(1):2379566. doi: 10.1080/19490976.2024.2379566. Epub 2024 Jul 16.
3
Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.
糖尿病肾病中肠道微生物群的变化:来自三重比较队列的见解
Front Cell Infect Microbiol. 2025 Jun 27;15:1606700. doi: 10.3389/fcimb.2025.1606700. eCollection 2025.
4
Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation.靶向糖尿病肾病中的离子通道网络:从分子串扰到精准治疗与临床创新
Front Med (Lausanne). 2025 Jun 26;12:1607701. doi: 10.3389/fmed.2025.1607701. eCollection 2025.
5
A bibliometric study of global trends in diabetic nephropathy and intestinal flora research.糖尿病肾病与肠道菌群研究全球趋势的文献计量学分析
Front Microbiol. 2025 May 21;16:1577703. doi: 10.3389/fmicb.2025.1577703. eCollection 2025.
6
Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024.2004年至2024年中医调节肠道微生物群治疗糖尿病的全球文献计量分析
Front Pharmacol. 2025 Jan 23;16:1533984. doi: 10.3389/fphar.2025.1533984. eCollection 2025.
7
A systematic review on gut microbiota in type 2 diabetes mellitus.关于2型糖尿病肠道微生物群的系统评价。
Front Endocrinol (Lausanne). 2025 Jan 17;15:1486793. doi: 10.3389/fendo.2024.1486793. eCollection 2024.
8
Diphenyl diselenide protects against diabetic kidney disease through modulating gut microbiota dysbiosis in streptozotocin-induced diabetic rats.二苯基二硒化物通过调节链脲佐菌素诱导的糖尿病大鼠肠道微生物群失调来预防糖尿病肾病。
Front Pharmacol. 2024 Dec 3;15:1506398. doi: 10.3389/fphar.2024.1506398. eCollection 2024.
姜黄素补充剂可减轻非酒精性单纯性脂肪性肝病患者的肝脂肪含量,其作用机制与调节肠道微生物群依赖性胆汁酸代谢有关:一项随机对照试验。
Am J Clin Nutr. 2024 Jul;120(1):66-79. doi: 10.1016/j.ajcnut.2024.05.017. Epub 2024 May 23.
4
Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic.益生菌治疗改善肠易激综合征患者的代谢组学相关心理共病。
Gut Microbes. 2024 Jan-Dec;16(1):2347715. doi: 10.1080/19490976.2024.2347715. Epub 2024 May 8.
5
Recipient microbiome-related features predicting metabolic improvement following fecal microbiota transplantation in adults with severe obesity and metabolic syndrome: a secondary analysis of a phase 2 clinical trial.接受者微生物组相关特征预测肥胖合并代谢综合征成人接受粪便微生物群移植后代谢改善:一项 2 期临床试验的二次分析。
Gut Microbes. 2024 Jan-Dec;16(1):2345134. doi: 10.1080/19490976.2024.2345134. Epub 2024 Apr 29.
6
Interindividual differences in aronia juice tolerability linked to gut microbiome and metabolome changes-secondary analysis of a randomized placebo-controlled parallel intervention trial.个体间对蓝莓汁耐受性的差异与肠道微生物组和代谢组的变化有关——一项随机安慰剂对照平行干预试验的二次分析。
Microbiome. 2024 Mar 9;12(1):49. doi: 10.1186/s40168-024-01774-4.
7
Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia.肠道微生物群-胆汁酸相互作用通过饮食诱导的人源化血脂异常中的肠 FXR-FGF19 轴调节小鼠的脂质代谢。
Microbiome. 2023 Nov 25;11(1):262. doi: 10.1186/s40168-023-01709-5.
8
Amelioration of Type 2 Diabetes Using Four Strains of Probiotics: Effects on Gut Microbiota Reconstitution-Mediated Regulation of Glucose Homeostasis, Inflammation, and Oxidative Stress in Mice.使用四种益生菌改善 2 型糖尿病:对肠道微生物组重建介导的葡萄糖稳态、炎症和氧化应激调节的影响。
J Agric Food Chem. 2023 Dec 27;71(51):20801-20814. doi: 10.1021/acs.jafc.3c04665. Epub 2023 Nov 22.
9
Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement.粪便微生物群移植通过菌株替换促进抗菌药物耐药性的减少。
Sci Transl Med. 2023 Nov;15(720):eabo2750. doi: 10.1126/scitranslmed.abo2750. Epub 2023 Nov 1.
10
Treg plasticity and human diseases.调节性 T 细胞可塑性与人类疾病。
Inflamm Res. 2023 Dec;72(12):2181-2197. doi: 10.1007/s00011-023-01808-x. Epub 2023 Oct 25.